- Campaign, Monday, September 23, 2019 9:26 AM
GSK is putting its $30m global creative account up for review,
Campaign writes. The site believes the review will cover vaccines and respiratory products, among others, which are believed to
account for around two-thirds of the pharmaceutical giant's business.
Read the whole story at Campaign »
